[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Rising Melanoma Cases Drive Demand for Skin Cancer Treatments According to Kalorama Information

13 Mar 2012 • by Natalie Aster

Rates of some cancers are declining, and survival rates of some cancers are increasing, but unfortunately melanoma statistics have gone in the opposition direction. According to healthcare market research publisher Kalorama Information, increasing incidence is driving demand for drugs to treat skin conditions such as melanoma.

The global market for prescription dermatological products grew at a rate of 10% from 2009 to 2011, according to “World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)” a market research report just released by Kalorama Information.

Report Details:

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
Published: March, 2012
Pages: 300
Price: US$ 3.995,00

Nearly 70,230 individuals in the United States – up from 68,720 just 2 years ago –will be diagnosed with melanoma in 2011, according to government estimates. Incidence rates for melanoma have been increasing for at least 30 years. In recent years, the increases have been most pronounced in young white women and in older white men. Melanoma is more than 10 times more common in Caucasians than in African Americans. It is slightly more common in men than in women. Overall, the lifetime risk of getting melanoma is about 2% (1 in 50) for Caucasians, 0.1% (1 in 1,000) for African Americans, and 0.5% (1 in 200) for Hispanics. The risk for each person can be affected by a number of different factors. Although the overall melanoma survival rates have improved over the past few decades, individuals with Stage III and Stage IV melanoma do not have good odds for survival. Survival in Stage III averages 35% to 50%, while Stage IV melanoma patients experience a 5% to 10% survival average.

More information can be found in the report “World Market for Prescription Dermatological Drugs, 8th Edition” by Kalorama Information.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com

Analytics & News

Weekly Digest